Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials?

被引：9
|
作者：
Januzzi, James L., Jr. [1 ,2 ]
机构：
[1] Massachusetts Gen Hosp, Cardiol Div, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA USA
来源：
JACC-HEART FAILURE | 2018年 / 6卷 / 07期
关键词：
biomarker; heart failure; outcomes;
D O I：
10.1016/j.jchf.2018.02.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：570 / 572
页数：3
相关论文
共 50 条
  • [31] NON-INFERIORITY TRIALS WITH A PRIMARY SURROGATE ENDPOINT: AN INCREASING PHENOTYPE IN CARDIOVASCULAR TRIALS
    Bikdeli, Behnood
    Caraballo-Cordovez, Cesar
    Welsh, John
    Ross, Joseph
    Stone, Gregg
    Krumholz, Harlan M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 1838 - 1838
  • [32] Biomarkers and surrogate endpoints in glaucoma clinical trials
    Medeiros, Felipe A.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (05) : 599 - 603
  • [33] Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology
    Bayes-Genis, Antoni
    Aimo, Alberto
    Jhund, Pardeep
    Richards, Mark
    de Boer, Rudolf A.
    Arfsten, Henrike
    Fabiani, Iacopo
    Lupon, Josep
    Anker, Stefan D.
    Gonzalez, Arantxa
    Castiglione, Vincenzo
    Metra, Marco
    Mueller, Christian
    Nunez, Julio
    Rossignol, Patrick
    Barison, Andrea
    Butler, Javed
    Teerlink, John
    Filippatos, Gerasimos
    Ponikowski, Piotr
    Vergaro, Giuseppe
    Zannad, Faiez
    Seferovic, Petar
    Rosano, Giuseppe
    Coats, Andrew J. S.
    Emdin, Michele
    Januzzi, James L.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1767 - 1777
  • [34] Nuclear Cardiology Surrogate Biomarkers in Clinical Trials
    Miller, Robert J. H.
    Patel, Krishna K.
    Kwiecinski, Jacek
    Slipczuk, Leandro
    Dweck, Marc
    Newby, David E.
    Chareonthaitawee, Panithaya
    Slomka, Piotr
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 4 - 11
  • [35] Endothelial function. A surrogate endpoint of clinical trials in cardiovascular medicine
    Ruschitzka, FT
    Noll, G
    Luscher, TF
    XIII WORLD CONGRESS OF CARDIOLOGY: FREE PAPERS, 1998, : 121 - 128
  • [36] Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
    Vaduganathan, Muthiah
    Claggett, Brian
    Packer, Milton
    McMurray, John J. V.
    Rouleau, Jean L.
    Zile, Michael R.
    Swedberg, Karl
    Solomon, Scott D.
    JACC-HEART FAILURE, 2018, 6 (07) : 564 - 569
  • [37] Redefining the role of biomarkers in heart failure trials: expert consensus document
    Frank Kramer
    Hani N. Sabbah
    James J. Januzzi
    Faiez Zannad
    J. Peter van Tintelen
    Erik B. Schelbert
    Raymond J. Kim
    Hendrik Milting
    Richardus Vonk
    Brien Neudeck
    Richard Clark
    Klaus Witte
    Wilfried Dinh
    Burkert Pieske
    Javed Butler
    Mihai Gheorghiade
    Heart Failure Reviews, 2017, 22 : 263 - 277
  • [38] Redefining the role of biomarkers in heart failure trials: expert consensus document
    Kramer, Frank
    Sabbah, Hani N.
    Januzzi, James J.
    Zannad, Faiez
    van Tintelen, J. Peter
    Schelbert, Erik B.
    Kim, Raymond J.
    Milting, Hendrik
    Vonk, Richardus
    Neudeck, Brien
    Clark, Richard
    Witte, Klaus
    Dinh, Wilfried
    Pieske, Burkert
    Butler, Javed
    Gheorghiade, Mihai
    HEART FAILURE REVIEWS, 2017, 22 (03) : 263 - 277
  • [39] Natriuretic peptides as a surrogate endpoint in clinical trials - a riddle wrapped in an enigma
    Hardwick, Alexander B.
    Ambrosy, Andrew P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (05) : 621 - 623
  • [40] Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials
    Weller, Michael
    NEURO-ONCOLOGY, 2011, 13 (06) : 565 - 565
12345